BRPI0514666A - antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes - Google Patents

antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes

Info

Publication number
BRPI0514666A
BRPI0514666A BRPI0514666-6A BRPI0514666A BRPI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A
Authority
BR
Brazil
Prior art keywords
combination
pdes
inhibitors
receptor antagonists
phosphodiestrase
Prior art date
Application number
BRPI0514666-6A
Other languages
English (en)
Inventor
Donald Jeffrey Keyser
Richard Dixon
Original Assignee
Encysive Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals filed Critical Encysive Pharmaceuticals
Publication of BRPI0514666A publication Critical patent/BRPI0514666A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ANTAGONISTAS DE RECEPTOR DE ENDOTELINA A (ET~ A~) EM COMBINAçãO COM INIBIDORES DE FOSFODIESTERASE 5 (PDES) E USOS DESTES A presente invenção refere-se em geral às terapias de combinação compreendendo um antagonista de receptor de endotelina A (ET~ A~) e um inibidor de fosfodiesterase 5 (PDE5), composições farmacêuticas compreendendo o antagonista de ET~ A~ e inibidor de PDE5 e métodos de tratar vários distúrbios compreendendo administrar um antagonista de ET~ A~ e um inibidor de PDE5. Em particular, as terapias de combinação e composições farmacêuticas são úteis para o tratamento e/ou prevenção de distúrbios cardíacos como hipertensão arterial pulmonar (PAH).
BRPI0514666-6A 2004-08-26 2005-08-26 antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes BRPI0514666A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60446204P 2004-08-26 2004-08-26
US11/211,099 US20060205733A1 (en) 2004-08-26 2005-08-25 Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
PCT/US2005/030342 WO2006026395A1 (en) 2004-08-26 2005-08-26 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0514666A true BRPI0514666A (pt) 2008-06-17

Family

ID=36000390

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514666-6A BRPI0514666A (pt) 2004-08-26 2005-08-26 antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes

Country Status (12)

Country Link
US (1) US20060205733A1 (pt)
EP (1) EP1789051A4 (pt)
JP (1) JP2008510830A (pt)
KR (1) KR20070074552A (pt)
AU (1) AU2005280077A1 (pt)
BR (1) BRPI0514666A (pt)
CA (1) CA2578044A1 (pt)
IL (1) IL181513A0 (pt)
MX (1) MX2007002311A (pt)
NO (1) NO20071446L (pt)
RU (1) RU2007110933A (pt)
WO (1) WO2006026395A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005273961A1 (en) * 2004-08-11 2006-02-23 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
KR20070084315A (ko) * 2004-11-18 2007-08-24 쉐링 코포레이션 울혈성 심장기능상실 치료용 ｐｄｅ ｖ 억제제의 사용 방법
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
EP1996582A2 (en) * 2006-03-13 2008-12-03 Encysive Pharmaceuticals, Inc Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-ý2-methyl-4,5-(methylenedioxy) phenylacetyl¨thiophene-3-sulfonamide, sodium salt
MX2008011842A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
US20070293552A1 (en) * 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP2101777B1 (en) 2006-12-12 2015-05-20 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US20090004268A1 (en) * 2007-03-13 2009-01-01 Given Bruce D Methods and Compositions for Treatment of an Interstitial Lung Disease
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
AU2013203192B2 (en) * 2007-06-11 2015-12-24 Edge Therapeutics Inc. A drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
WO2009046848A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
NZ610012A (en) * 2010-10-15 2015-05-29 Gilead Sciences Inc Compositions and methods of treating pulmonary hypertension
HK1198933A1 (en) 2011-04-05 2015-06-19 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
ES2651293T3 (es) * 2012-01-31 2018-01-25 Eisai R&D Management Co., Ltd. Derivado de sitaxentán
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
US20160015701A1 (en) * 2013-03-08 2016-01-21 Abbive Inc. Methods of Treating Acute Kidney Injury
RU2763525C2 (ru) * 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
KR102896033B1 (ko) * 2022-12-22 2025-12-04 연세대학교 산학협력단 N-벤질퀴나졸린-4-아민 화합물을 포함하는, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
JP2004525890A (ja) * 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
NO20071446L (no) 2007-03-26
AU2005280077A1 (en) 2006-03-09
WO2006026395A1 (en) 2006-03-09
MX2007002311A (es) 2008-03-10
EP1789051A4 (en) 2009-10-21
JP2008510830A (ja) 2008-04-10
US20060205733A1 (en) 2006-09-14
KR20070074552A (ko) 2007-07-12
CA2578044A1 (en) 2006-03-09
RU2007110933A (ru) 2008-10-10
EP1789051A1 (en) 2007-05-30
IL181513A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0514666A (pt) antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes
CY1121338T1 (el) Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
BR112013008140A2 (pt) "compostos imidazotriazinona".
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
NO20071048L (no) Amidoforbindelser og deres anvendelse som farmasoytika
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BRPI0512630A (pt) compostos de amido e seu uso como produtos farmacêuticos
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
NO20072599L (no) Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
BRPI0518105A (pt) uso de antagonista da angiogênese e uso de anticorpo anti-vegf
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.